Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Certolizumab Pegol in Moderate to Severe Chronic Plaque Psoriasis
2014-003486-14Phase 3Completed
- Sponsor
- UCB
- Start
- Jan 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in plaque psoriasis (2 arms), sponsored by UCB. Primary endpoint: PASI 75 at Week 16. Started Jan 2015; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2014-003486-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003486-14.